The company, founded in 2003 and based in Cambridge, Massachusetts, is dedicated to discovering and developing disease-modifying drugs for diseases caused by protein misfolding and amyloidosis. Their pipeline includes a program targeting genetic neurologic and cardiovascular disorders, specifically transthyretin-associated amyloidoses with polyneuropathy and TTR-associated amyloidoses with cardiomyopathy. They also have a discovery program in place for Parkinson's disease and cystic fibrosis. By addressing the accumulation of misfolded proteins resulting from mutations or defects in cellular quality control mechanisms, FoldRx Pharmaceuticals aims to provide healthcare professionals with effective therapies to treat protein misfolding diseases.